Imogen A Ball
Overview
Explore the profile of Imogen A Ball including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
90
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li A, Bowen J, Ball I, Wilson S, Yong A, Yeung D, et al.
Biomedicines
. 2023 Dec;
11(12).
PMID: 38137495
Haematopoietic stem cell transplantation (HSCT) is a curative approach for blood cancers, yet its efficacy is undermined by a range of acute and chronic complications. In light of mounting evidence...
2.
Korver S, Bowen J, Gibson R, Ball I, Secombe K, Wain T, et al.
Cancer Chemother Pharmacol
. 2023 May;
91(6):507-521.
PMID: 37162533
Purpose: Adverse effects following fluoropyrimidine-based chemotherapy regimens are common. However, there are no current accepted diagnostic markers for prediction prior to treatment, and the underlying mechanisms remain unclear. This study...
3.
Secombe K, Ball I, Wignall A, Bateman E, Keefe D, Bowen J
Neoplasia
. 2022 May;
30:100806.
PMID: 35561424
Background: Neratinib is a pan-ErbB tyrosine kinase inhibitor used for extended adjuvant treatment of HER2-positive breast cancer. Diarrhea is the main adverse event associated with neratinib treatment. We aimed here...
4.
Secombe K, Ball I, Shirren J, Wignall A, Keefe D, Bowen J
Breast Cancer
. 2020 Jul;
28(1):99-109.
PMID: 32683606
Background: Neratinib is a potent irreversible pan-ErbB tyrosine kinase inhibitor, approved by the FDA for extended adjuvant treatment of HER2-positive breast cancer. Diarrhea is the most frequently observed adverse event...
5.
Chiam K, Mayne G, Wang T, Watson D, Irvine T, Bright T, et al.
World J Gastroenterol
. 2020 Jun;
26(20):2570-2583.
PMID: 32523312
Background: Circulating microRNAs (miRNAs) are potential biomarkers for many diseases. However, they can originate from non-disease specific sources, such as blood cells, and compromise the investigations for miRNA biomarkers. While...
6.
Gibson R, Van Sebille Y, Wardill H, Wignall A, Shirren J, Ball I, et al.
Chemotherapy
. 2019 Feb;
63(5):284-292.
PMID: 30731451
Background: The common cytotoxic mechanisms that underpin chemoefficacy and toxicity have hampered efforts to deliver effective supportive care interventions, particularly for gastrointestinal (GI) toxicity. Matrix metalloproteinases (MMPs) have been implicated...
7.
Secombe K, Ball I, Shirren J, Wignall A, Finnie J, Keefe D, et al.
Cancer Chemother Pharmacol
. 2018 Dec;
83(3):531-543.
PMID: 30535958
Purpose: Neratinib is an irreversible pan-ErbB tyrosine kinase inhibitor used for the extended adjuvant treatment of early-stage HER2-positive breast cancer. Its use is associated with the development of severe diarrhea...
8.
Van Sebille Y, Gibson R, Wardill H, Ball I, Keefe D, Bowen J
Int J Cancer
. 2017 Sep;
142(2):369-380.
PMID: 28921512
Dacomitinib, an irreversible small-molecule pan-ErbB TKI, has a high incidence of diarrhea, which has been suggested to be due to chloride secretory mechanisms. Based on this hypothesis, crofelemer, an antisecretory...
9.
Van Sebille Y, Gibson R, Wardill H, Secombe K, Ball I, Keefe D, et al.
Int J Cancer
. 2017 Mar;
140(12):2820-2829.
PMID: 28316082
Dacomitinib-an irreversible pan-ErbB tyrosine kinase inhibitor (TKI)-causes diarrhoea in 75% of patients. Dacomitinib-induced diarrhoea has not previously been investigated and the mechanisms remain poorly understood. The present study aimed to...
10.
Coller J, Bowen J, Ball I, Wardill H, Van Sebille Y, Stansborough R, et al.
Cancer Chemother Pharmacol
. 2016 Dec;
79(2):431-434.
PMID: 28011980
Purpose: Irinotecan-induced gut toxicity is mediated in part by Toll-Like receptor 4 (TLR4) signalling. The primary purpose of this preclinical study was to determine whether blocking TLR4 signalling by administering...